Focused on seeding early stage biotech therapeutics and related AI opportunities. The fund will invest in companies qualifying under EIS and covering novel drug discovery along with enabling services, tools and AI technologies.

the o2h knowledge intensive EIS fund is an HMRC approved fund that invests in EIS qualifying biotech companies along with enabling services, tools and AI technologies. Two part investment focus of Access & Incubation, providing unique opportunities and reducing investment risk by being deeply involved.

The o2h human health S/EIS fund is a hybrid fund that is investing in EIS and SEIS qualifying seed stage companies covering novel drug discovery along with enabling services, tools and AI technologies.

2025年3月13日 · The o2h Human Health SEIS Fund is an unapproved SEIS fund targeting a 2.5x return to investors. The fund invests into a portfolio of a minimum of 3 unquoted and/or AIM Listed companies with a focus on Biotechnology and Life Sciences. Investment is done at the Pre-Seed stage with typical investments of between £50k-£1m per company. Fee Notes

2019年1月31日 · o2h Ventures Limited, an investment firm based in Cambridge, UK, has now launched “the o2h Therapeutics Fund” an early stage SEIS and/or EIS fund backing biotech therapeutic and related AI opportunities with plug-in capabilities in Cambridge, UK/India and a bridge to the USA.

O2h Therapeutics EIS Fund is a 2020 vintage venture capital fund managed by O2h Ventures. The fund is based in Cambridge, United Kingdom, and invests in the United Kingdom. The fund targets investments in the healthcare, information technology, artificial intelligence & machine learning, and life science sectors and prefers to invest in 5 to 10 ...

The o2h Human Health Knowledge-Intensive EIS fund is the first HMRC approved knowledge intensive EIS fund in the UK. It provides investors with the opportunity to invest in the growth potential of UK novel drug discovery and AI businesses. It has created an integrated model for supporting investee companies.

2023年6月29日 · The o2h Human Health EIS Knowledge Intensive Fund is a discretionary managed portfolio service structured as an Alternative Investment Fund and focused on investing in a portfolio of companies that develop therapeutics or supply services to such companies.

Cambridge, UK, 05 August 2021: o2h Ventures is delighted to announce an investment into BiVictriX Therapeutics, an emerging biotechnology company applying a novel approach to develop next-generation cancer therapies using insights derived from frontline clinical experience.

2024年2月20日 · The o2h therapeutics S/EIS Fund, our predecessor, has showcased promising returns, with a current unrealized total return of 1.83x. Valuations are based on the last investment round. 12 out of 19 of the portfolio companies in that fund have raised further funding rounds with a significant uplift in their valuations.